Skip to content
Search

Investment involves risk. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.

Australian Unit Trust
Global Equity Fund
High conviction, global equity portfolio seeking to invest in companies with above-average and sustainable growth characteristics.  

Class S PDS

Class I PDS

Client Fund Profile

Annual Report
APIR ETL0071AU
PERFORMANCE REPORT
Product Disclosure Statement
QUARTERLY REVIEW
Exit Icon

The Quarterly Review report is not available. Please check back soon.

OK
Target Market Determination
Exit Icon

The performance report as of the previous month end is not available. Please check back soon.

Exit Icon

The Product Disclosure Statement for this fund is not currently available. Please check back soon.

No data available
30-Apr-2025 - Scott Berg Portfolio Manager,
U.S. President Trump’s 2 April tariff announcement meaningfully changed our outlook on global equities and the global economy. While we feel worse about recession risk in the near term, we think we are now operating in a world of broader investment opportunities spread across both sectors and regions, serving as an enticing backdrop for active investors.

Overview
Strategy
Fund Summary
High conviction, truly global equity portfolio seeking to invest in companies with above-average and sustainable growth characteristics.
Performance - Net of Fees

Past performance is not a reliable indicator of future performance.

Current Year Performance

Annualised Performance

30-Apr-2025 - Scott Berg Portfolio Manager,
In Australian dollar terms, global equities showed mixed performance in April during a highly volatile month of trading. Investors navigated significant market turbulence primarily triggered by President Donald Trump's reciprocal tariffs announced on April 2, which were more severe than anticipated. A partial recovery occurred on April 9 when Trump declared a 90-day pause on these tariffs for many countries except China. Within the portfolio, holdings in financials detracted the most from relative returns. Shares of one of the largest private banks in Vietnam pulled back along with the broader Vietnamese market amid macroeconomic concerns following President Trump’s reciprocal tariff announcement on April 2. We continue to think the company represents compelling, high-quality exposure to an attractive and demographically growing region. On the positive side, health care names contributed to relative results. Shares of a Japanese pharmaceutical firm spiked in April after reporting strong earnings results, driven by robust export sales of all key products. Management also indicated a high level of confidence in the upcoming phase 1 and 2 trial data release for its drug to treat haemophilia A. We have conviction in the firm, which we view as Japan’s best pharmaceutical research and development house.

Team

No data available

Fees

No data available

Benchmark Data Source: MSCI. MSCI index returns are shown with reinvestment of dividends after the deduction of withholding taxes. MSCI and its affiliates and third party sources and providers (collectively, “MSCI”) makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

 

The specific securities identified and described in this website do not represent all of the securities purchased or sold for this fund. This information is not intended to be a recommendation to take any particular investment action and is subject to change. No assumption should be made that the securities identified were or will be profitable.

Unless otherwise specified, all fund ratings, awards and data are as of 30-Apr-2025 and sourced from T. Rowe Price. 

©2023 Morningstar, Inc. All rights reserved. The information  contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Equity Trustees Limited (“Equity Trustees”) (ABN 46 004 031 298 AFSL 240975) is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Stock Exchange (ASX:EQT). Equity Trustees and T. Rowe Price Australia Limited ("TRPAU") (ABN: 13 620 668 895 and AFSL: 503741) are, respectively, the responsible entity and investment manager of the T. Rowe Price Australian Unit Trusts. A Target Market Determination for each T. Rowe Price Australian Unit Trust (or class of units in a Trust) is available here (http://www.eqt.com.au/insto). It describes who the financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where Equity Trustees Limited, the responsible entity of the T. Rowe Price Australian Unit Trusts may need to review the Target Market Determination for the financial product.

For Wholesale Clients only.

Past performance is not a reliable indicator of future performance. The price of any fund may go up or down. Investment involves risk including a possible loss to the principal amount invested. For general information purposes only, does not take into account the investment objectives, financial situation or needs of any particular investor. For further details, please refer to each fund's product disclosure statement and reference guide which are available from Equity Trustees (www.eqt.com.au/insto) or TRPAU (www.troweprice.com.au).

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.